Patient-experience themes¶
Last curated: 2026-08-29. Each theme is supported by at least two live-resolved PubMed sources. Most evidence concerns hypertension or HF/HFpEF rather than a directly recruited HHD cohort.
1. The disease can feel absent while treatment is always present¶
Hypertension is often symptomless. Daily tablets, refills, BP checks, diet changes and appointments can therefore feel more concrete than the prevented outcome. This time-horizon mismatch shapes adherence and risk communication (Zhou 2024, PMID 38549805; Khatib 2014, PMID 24454721).
Design implication: explain the purpose of treatment in the patient’s own horizon—preserving walking, work, cognition, kidney function and independence—not only in abstract lifetime risk.
2. “Nonadherence” often contains several different problems¶
Qualitative syntheses identify cost, access, side effects, regimen complexity, forgetfulness, beliefs, competing responsibilities, and weak clinician communication. A single adherence percentage hides these mechanisms (Zhou 2024, PMID 38549805; Ghaderi Nasab 2024, PMID 39628801).
Design implication: measure acquisition, initiation, implementation and persistence separately; match intervention to cause.
3. Access failures masquerade as individual choices¶
Rural Kenyan and multi-country chronic-care studies describe transport, clinic availability, medicine stock, indirect cost and fragmented follow-up as determinants of treatment (Oyando 2025, PMID 41270024; Pesantes 2020, PMID 31596656).
Design implication: count travel, waiting, stock-outs and out-of-pocket costs as outcomes.
4. Explanatory models influence action¶
People may interpret hypertension as episodic stress, a symptomatic state, hereditary fate, or a condition requiring medication only when readings are high. Women living with hypertension and displaced populations describe culturally and socially embedded models rather than simple knowledge deficits (Kc 2023, PMID 36974856; Shahin 2021, PMID 35480607).
Design implication: ask what the person thinks causes BP variation before correcting or prescribing.
5. Home monitoring can create agency—or vigilance burden¶
Self-monitoring combined with co-intervention can improve BP, but device access, technique, interpretation and sustained use determine whether it empowers or burdens (Tucker 2017, PMID 28926573; Gantagad 2025, PMID 41189998).
Design implication: provide a response pathway for readings; data collection without actionable feedback can amplify anxiety.
6. Digital interventions are not interchangeable with care¶
Digital programs can support titration and self-management, yet results vary with clinical integration. A smartphone application alone and a structured digital-plus-clinical intervention are different exposures (Persell 2020, PMID 32119093; McManus 2021, PMID 33468518).
Design implication: describe who reviews measurements, response time, escalation authority, device/data costs and language accessibility.
7. Severe hypertension changes goals¶
People with difficult-to-treat hypertension may prioritize avoiding stroke, reducing pill burden, gaining trustworthy explanations, and retaining everyday function. Device enthusiasm cannot be inferred from BP severity alone (Hill 2026, PMID 42321603; Zhou 2024, PMID 38549805).
Design implication: renal-denervation and resistant-hypertension trials should measure treatment burden, expectations and decisional regret alongside BP (Vukadinović 2024, PMID 39355923).
8. Symptom burden expands after HF develops¶
HF experience includes breathlessness, fatigue, impaired mobility, disrupted identity, dependence and uncertainty. HFpEF patients and caregivers report substantial quality-of-life effects even when the biomedical label is poorly understood (Niklasson 2022, PMID 35081667; Rubio 2025, PMID 40649089).
Design implication: pre-HF HHD studies need symptom and function baselines so progression is visible before hospitalization.
9. Self-management is relational work¶
HF self-management relies on family, caregivers and clinicians for food, medicines, monitoring, transport, interpretation and emergency decisions (Frost 2025, PMID 40625643; Niklasson 2022, PMID 35081667).
Design implication: measure caregiver work and include the chosen support person where the patient wants this.
10. Trust and continuity are treatment mechanisms¶
Studies in Tanzania, Ethiopia and Malawi describe communication, continuity, respectful care, local service capacity and medicine access as intertwined rather than separable barriers (Galson 2023, PMID 36608026; Endrias 2024, PMID 39702319; Ogugu 2024, PMID 38678232).
Design implication: a technically correct prescription is not an effective intervention if the delivery relationship fails.
11. Community delivery can alter the feasible choice set¶
Village-doctor and home-based programs changed where care occurred, who delivered it and how follow-up worked. Their effects cannot be reduced to patient education (Sun 2022, PMID 35500594; Siedner 2025, PMID 40888742).
Design implication: evaluate implementation as an active component, including workforce, supply chain and escalation pathways.
12. The label “heart damage” may help and harm¶
HHD reviews and biomarker-staging work create increasingly early labels, but the emotional, behavioral and insurance/social effects of those labels are not established (Nwabuo 2020, PMID 32016791; Sharp 2026, PMID 41771092).
Design implication: embed qualitative work in phenotype studies before assuming that earlier naming improves prevention.
Cross-theme outcome matrix¶
| Outcome | Why it matters | Most relevant themes |
|---|---|---|
| BP control | Intermediate prevention target | 1–6, 10–11 |
| Medication persistence | Sustained exposure | 1–4, 10 |
| Treatment burden | Net value of prevention | 1, 5–7 |
| Financial toxicity | Access and equity | 3, 6, 11 |
| Anxiety / reassurance | Consequence of monitoring and labeling | 5, 12 |
| Function | Patient-valued endpoint | 7–9 |
| Caregiver burden | Hidden work | 8–9 |
| Trust / continuity | Delivery mechanism | 3, 10–11 |
| Decisional regret | Device and intensive-treatment choice | 7 |
| Hospital-free days | Clinical and lived outcome | 8–9 |